CD4 and COVID-19: A clinical trial with COVID-19 vaccine BNT162b1 has also shown that the strength of the vaccine-induced RBD-specific CD4+ T cell responses is positively correlated with neutralizing antibody titers against SARS-CoV-2 (17).